| Ladysmith Care & Rehab | |
| 900 College Ave W, Ladysmith, Wisconsin 54848 | |
| (715) 532-5015 | |
| Name | Ladysmith Care & Rehab |
|---|---|
| Location | 900 College Ave W, Ladysmith, Wisconsin |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 50 |
| Occupancy Rate | 58.2% |
| Medicare ID (CCN) | 525416 |
| Legal Business Name | Senior Management Inc |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1063765477 |
| Organization Name | SENIOR MANAGEMENT INC |
| Address | 900 College Ave W, Ladysmith, WI 54848 |
| Phone Number | 715-532-9809 |
News Archive
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
The abstract submission deadline of February 4th is only one week away! Ensure that your research appears at the most important international osteoporosis meeting of the year, the IOF WCO-ECCEO10. Click here to submit your abstract online: http://www.iofwco-ecceo10.org/abstracts/
Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.
Researchers have released a new Capsicum annuum pepper germplasm that contains high concentrations of capsinoids.
Last summer, SLU scientists made a breakthrough discovery about the way in which blood clots. Through X-ray crystallography, they solved the molecular structure of prothrombin, an important blood-clotting protein, revealing an unexpected, flexible role for a "linker" region that may be the key to developing better life-saving drugs.
› Verified 5 days ago
| NPI Number | 1316098478 |
| Organization Name | COUNTY OF RUSK DBA RUSK COUNTY MEMORIAL HOSPITAL AND NURSING HOME |
| Address | 900 College Ave W, Ladysmith, WI 54848 |
| Phone Number | 715-532-5561 |
News Archive
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
The abstract submission deadline of February 4th is only one week away! Ensure that your research appears at the most important international osteoporosis meeting of the year, the IOF WCO-ECCEO10. Click here to submit your abstract online: http://www.iofwco-ecceo10.org/abstracts/
Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.
Researchers have released a new Capsicum annuum pepper germplasm that contains high concentrations of capsinoids.
Last summer, SLU scientists made a breakthrough discovery about the way in which blood clots. Through X-ray crystallography, they solved the molecular structure of prothrombin, an important blood-clotting protein, revealing an unexpected, flexible role for a "linker" region that may be the key to developing better life-saving drugs.
› Verified 5 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical results presented at the AACR-IASLC (American Academy of Cancer Research – International Association for the Study of Lung Cancer) Joint Conference based on work done at Synta and at the Dana-Farber Cancer Institute in Boston showed that STA-9090, a potent, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated potent activity against 100% of all non-small cell lung cancer cell lines tested, including those with EGFR, HER2 or KRAS mutations including the EGFR T790 mutation that is present in roughly 50% of cases of erlotinib or gefitinib resistance.
The abstract submission deadline of February 4th is only one week away! Ensure that your research appears at the most important international osteoporosis meeting of the year, the IOF WCO-ECCEO10. Click here to submit your abstract online: http://www.iofwco-ecceo10.org/abstracts/
Yale Cancer Center researchers have developed a vaccine strategy that reduces the risk of flu infections in cancer patients at highest risk for influenza. The findings were presented Dec. 6 at the 57th annual meeting of the American Society of Hematology in Orlando, Florida.
Researchers have released a new Capsicum annuum pepper germplasm that contains high concentrations of capsinoids.
Last summer, SLU scientists made a breakthrough discovery about the way in which blood clots. Through X-ray crystallography, they solved the molecular structure of prothrombin, an important blood-clotting protein, revealing an unexpected, flexible role for a "linker" region that may be the key to developing better life-saving drugs.
› Verified 5 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 14 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 2.73 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 46.3 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 13.9 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 7.69 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 3.7 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 0 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 88.14 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 11.02 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 74.68 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 0 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 21.65 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 10.81 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 5.13 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 100 | 95.98 |